Intensity Therapeutics, Inc.
INTS
Rank in Stocks
#29210
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$8.51M
Change (1 day)
5.00%
Change (1 year)
-75.39%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Intensity Therapeutics, Inc. (INTS)
Category
Healthcare
Number of shares outstanding for Intensity Therapeutics, Inc. (INTS)
Number of shares outstanding as of September 2026: 3.26M
According to Intensity Therapeutics, Inc.'s latest financial reports, its current number of shares outstanding is 3.26M. At the end of 2025 the company had 1.36M shares outstanding. The number of shares outstanding usually changes with stock splits and share buybacks.
Shares outstanding history for Intensity Therapeutics, Inc. (INTS) from 2019 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 3.26M | 140.14% |
| 2025 | 1.36M | 143.84% |
| 2024 | 556.24K | 81.68% |
| 2023 | 306.16K | 124.46% |
| 2022 | 136.40K | 0.00% |
| 2021 | 136.40K | 0.03% |
| 2020 | 136.36K | 0.21% |
| 2019 | 136.08K | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.50M | 7,682.98% |
US
|
|
| 401.00M | 12,211.53% |
US
|
|
| 478.91M | 14,603.59% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.74M | 1,826.11% |
NL
|
Questions about Intensity Therapeutics, Inc.'s number of shares outstanding
What is Intensity Therapeutics, Inc.'s number of shares outstanding?
Intensity Therapeutics, Inc.'s number of shares outstanding is 3.26M, as of Sep 2026.
What was Intensity Therapeutics, Inc.'s number of shares outstanding in 2025?
In 2025, Intensity Therapeutics, Inc.'s number of shares outstanding was 1.36M, 143.84% more than in 2024 (556.24K).
How has Intensity Therapeutics, Inc.'s number of shares outstanding changed since 2020?
From 2020 to 2025, Intensity Therapeutics, Inc.'s number of shares outstanding went from 136.36K to 1.36M, an average growth of 58.32% a year.